|
Originally published In Press as doi:10.1074/jbc.M107511200 on September 11, 2001
J. Biol. Chem., Vol. 276, Issue 46, 42700-42706, November 16, 2001
Folding and Subunit Assembly of Photoreceptor
Peripherin/rds Is Mediated by Determinants within the
Extracellular/Intradiskal EC2 Domain
IMPLICATIONS FOR HETEROGENEOUS MOLECULAR PATHOLOGIES*
Andrew F. X.
Goldberg ,
Linda M.
Fales,
James B.
Hurley§, and
Nidhi
Khattree
From the Eye Research Institute, Oakland University, Rochester,
Michigan 48309 and § Howard Hughes Medical Institute,
Department of Biochemistry, University of Washington, Seattle,
Washington 98195
Received for publication, August 6, 2001
 |
ABSTRACT |
Peripherin/rds is an integral
membrane protein required for the elaboration of rod and cone
photoreceptor outer segments in the vertebrate retina; it causes a
surprising variety of progressive retinal degenerations in humans and
dysmorphic photoreceptors in murine models if defective or absent.
(Peripherin/rds is also known as photoreceptor peripherin,
peripherin/rds, rds/peripherin, rds, and peripherin-2.)
Peripherin/rds appears to act as a structural element in outer segment
architecture. However, neither its function at the molecular level nor
its role in retinal disease processes are well understood. This report
initiates a systematic investigation of protein domain structure and
function by examining the molecular and cellular consequences of a
series of 14 insertional mutations distributed throughout the
polypeptide sequence. Protein expression, disulfide bonding,
sedimentation velocity, and subcellular localization of the COS-1
cell-expressed mutant variants were examined to test the hypothesis
that protein folding and tetrameric subunit assembly are mediated
primarily by EC2, a conserved extracellular/intradiskal domain. Protein
folding and tetrameric subunit assembly were not affected by insertion
of either an uncharged dipeptide (GA) or a highly charged
hendecapeptide (GDYKDDDDKAA) into any one of nine sites residing
outside of EC2 as assayed by nonreducing Western blot analysis,
sedimentation velocity, and subcellular localization. In contrast,
insertions at five positions within the EC2 domain did cause either
gross protein misfolding (two sites) or a reduction in protein
sedimentation coefficient (two sites) or both (one site). These results
indicate that although the vast majority of extramembranous polypeptide
sequence makes no measurable contribution to protein folding and
tetramerization, discrete regions within the EC2 domain do contain
determinants for normal subunit assembly. These findings raise the
possibility that multiple classes of structural perturbation are
produced by inherited defects in peripherin/rds and contribute
to the observed heterogeneity of retinal disease phenotypes.
 |
INTRODUCTION |
The outer segments
(OSs)1 of rod and cone
photoreceptor cells act as detectors of visible light for the initial
stages of the visual process and are vital for normal vertebrate
vision. The OS is an architecturally complex organelle. It contains
hundreds of precisely stacked membranous disks that undergo a polarized renewal process; a complete turnover of OS membrane protein occurs approximately once every 10 days in primate rod cells (1). Although the
renewal process and OS stability are essential for photoreceptor
viability, their underlying molecular bases remain largely undefined.
Evidence from several laboratories has implicated the integral membrane
protein peripherin/rds in OS morphogenesis and the renewal process
(2-4). It is present in all vertebrate rod and cone photoreceptors
examined to date and causes a variety of progressive retinal diseases
in humans when defective (5).
Despite continued interest and study, neither the normal molecular
action of peripherin/rds in OS renewal nor its role in the
pathophysiology of retinal disease is well understood. Several suggestions for molecular function have been proposed based largely on
the molecular genetic identification of peripherin/rds as the primary
trigger for the murine retinal degeneration slow
(rds) phenotype and the immunochemical localization
of this protein to rod and cone OS disc rim regions (6, 7). Proposals
for function include stabilization of the highly curved disc rims, maintenance of flattened disc structure through adhesive interactions, morphogenesis of disc membranes/rim regions, catalysis of disc shedding, and/or scaffolding of disc stacks (2, 8-11). The recent
finding that OS morphogenesis as well as photoreceptor function can be
rescued in postnatal (10-day-old) rds mice reinforces the
notion that this protein is a building block for the normally continuous OS renewal process (12). In addition, the reported flattening of canine pancreatic microsomes by peripherin/rds in vitro is consistent with a direct role in OS structure (13). Current studies are directed at resolving the molecular details of
peripherin/rds action.
The cloning and identification of nearly a dozen highly conserved
peripherin/rds orthologs (from humans to fish) has suggested that the
proteins share several distinctive features, including four hydrophobic
transmembrane segments, a large extracellular/intradiskal loop domain
(EC2), seven conserved cysteine residues, and a covalently attached
carbohydrate moiety (3, 14-22). Hydrodynamic studies performed under
reducing conditions indicate that WT peripherin/rds polypeptides can
self-assemble to form homotetramers and also can co-assemble with rom-1
(a homologous polypeptide) to form heterotetramers (10, 23). The
noncovalently associated tetramers can join via disulfide bonds to
generate larger polymers of indeterminate size; polymerization appears
to be mediated by a single conserved cysteine residue in peripherin/rds
and inhibited by the presence of rom-1 (24, 25). Although
tetramerization and polymerization are believed integral for function,
their place in the mechanism of peripherin/rds action has yet to be
established. Because OS formation is observed in the complete absence
of rom-1 (26), peripherin/rds-containing tetramers appear to be the
essential units of function for OS morphogenesis.
Several instances of inherited retinal degeneration have been
associated with the disruption of peripherin/rds folding and subunit
assembly, yet other cases do not appear to impact these processes at
all (24, 27). Such observations of discrete (versus global)
disruptions caused by missense mutations has led us to question whether
partial loss-of-function defects may account for some of the phenotypic
heterogeneity characteristic of peripherin/rds-associated retinal
diseases. To improve our understanding of protein domain structure and
function, we have initiated an insertional mutagenesis approach similar
to one taken previously for rhodopsin (28). This report provides
evidence in support of the hypothesis that the EC2 domain is
particularly important for proper folding and subunit assembly of
peripherin/rds.
 |
EXPERIMENTAL PROCEDURES |
Design and Construction of Phase I and Phase II Mutants--
A
series of 14 Phase I insertion mutants, each containing a unique Nar I
endonuclease restriction site (5'-GGCGCC-3'), was constructed using
subcloned regions of the WT peripherin/rds sequence as templates,
synthetic oligonucleotide primers (Table
I), and methods described previously
(29). The presence of designed, and absence of spurious, mutations was
confirmed by complete (single-stranded) DNA sequencing using a BigDye
terminator cycle sequencing cycle kit (Applied Biosystems, Inc.).
Mutagenized regions were returned to a WT peripherin/rds expression
vector background by subcloning, and final constructs were confirmed by
restriction mapping. Each Phase I mutation introduces a dipeptide (GA)
into the WT protein sequence at the indicated position (see Fig.
1).
View this table:
[in this window]
[in a new window]
|
Table I
Synthetic oligonuclueotides used for Phase I mutagenesis
Synthetic oligonucleotide primers (shown) were employed to create 14 Phase I insertion mutants using a WT peripherin/rds template; each
contains a unique Nar I endonuclease restriction site (underlined).
Polymerase chain reaction methods and template subclones have been
described previously (24).
|
|
A series of 14 Phase II mutations was constructed by ligation of a FLAG
epitope cassette (30) flanked by Nar I sticky ends (sense,
5'-CGACTACAAGGACGACGACGACAAGGC-3'; antisense,
5'-CGGCCTTGTCGTCGTCGTCCTTGTAGT-3') into the Phase I mutants described.
The presence, copy number, and orientation of the FLAG cassette were
determined by DNA sequencing with a BigDye terminator cycle sequencing
kit (Applied Biosystems, Inc.). Each of the Phase II mutants contains a
nonapeptide insertion encoding a FLAG epitope (DYKDDDDKA) at the
indicated position within the Phase I mutant sequences (see Fig.
1).
Generation and Characterization of Immunochemical
Reagents--
Anti-peripherin/rds monoclonal antibody C6 was a kind
gift of Dr. John Saari and Dr. Krzysztof Palczewski of the Department of Ophthalmology at the University of Washington. Anti-rom-1 polyclonal antibody MUTT was generated by immunization of New Zealand White rabbits with an affinity-purified glutathione
S-transferase fusion protein. The coding sequence for the
C-terminal hydrophilic domain of bovine rom-1 was amplified from a
GT-11 bovine retinal library and then cloned in-frame into the
pGEX-2T expression vector. Bacterial fusion protein expression and
affinity purification were performed essentially as described (31).
Each antibody was characterized with respect to its specificity in
Western blot analyses using authentic proteins from rod outer
segment membranes, and recombinant proteins were expressed in COS-1
cells; no cross-reactivity was observed. The anti-peripherin/rds
monoclonal antibody (MAb) C6 epitope was mapped using a series of
synthetic peptides kindly provided by Dr. Kathleen Boesze-Battaglia,
and it was found to reside within 15 amino acids of the full-length
protein C terminus. It was not expected to be affected by any of the
mutations examined in this report. Peptide competition was also used to
confirm MAb C6 specificity for other immunochemical procedures,
including immunofluorescence localization and immunoprecipitation
studies not reported here.
Assay of Expression and Disulfide Bonding in COS-1
Cells--
COS-1 cells (~1 × 106/100-mm
dish) were transfected with the FuGENE 6 reagent (Roche Diagnostics
Co.) and 8 µg of the indicated expression plasmid essentially as
suggested by the manufacturer. Detergent extracts were prepared using
1% Triton X-100 in phosphate-buffered saline at 48 h
post-transfection essentially as described (30). Methods for
Western blot analysis of recombinant peripherin/rds expression and
disulfide bonding have been reported previously (23).
Subcellular Localization in COS-1 by
Immunocytochemistry--
COS-1 cells (~3 × 104/4-cm2 slide chamber) were transfected with
FuGENE 6 (Roche Diagnostics Co.) and 1 µg of the indicated expression
plasmid essentially as suggested by the manufacturer. Cells were fixed
briefly with 4% paraformaldehyde, permeabilized with Triton X-100, and
processed using MAb C6 and a secondary anti-mouse IgG covalently
labeled with the Cy3 fluorophore (Amersham Pharmacia Biotech)
essentially as described (23). Images were collected with a Nikon
Optiphot-2 microscope equipped with an epi-fluorescent illuminator and
a SPOT RT digital imaging system (Diagnostic Instruments Inc., v3.0 software).
Assay of Subunit Assembly by Velocity
Sedimentation--
S20, w
estimates were made in a Beckman Optima TLX centrifuge using a
TLA-55 rotor or in a Sorvall RC-M120EX centrifuge using an RP55-S rotor
as described (29) but with the following modifications. Sucrose
gradient fractions (2.1-ml) were collected by piercing tube bottoms in
an offset fashion; particulate fractions were obtained by resealing
punctured centrifuge tubes with laboratory film, adding 90 µl of 1×
Laemmli sample buffer and vortexing vigorously. Digital analysis of
chemiluminescent Western blots was performed using Scion Image
software (Scion Corp.). Total peripherin/rds reactivity was
calculated by pixel summation over soluble and particulate fractions.
 |
RESULTS |
Design and Construction of Phase I and Phase II
Mutants--
Regions of peripherin/rds consensus sequence predicted to
form hydrophilic domains were evaluated for their tendency to form polypeptide secondary structure, and 14 sites within regions lacking strongly predicted structural motifs were identified (Fig.
1). A series of 14 Phase I mutants, each
containing a unique Nar I endonuclease restriction site, were
constructed using synthetic oligonucleotides and the polymerase chain
reaction. These mutations were designed to produce minimal perturbation
to protein structure as they add only two relatively small, uncharged
amino acids (GA) to the WT sequence. An additional series of 14 Phase
II mutants, expected to be more highly disruptive, was constructed by
ligation of a single copy FLAG epitope cassette (coding for a
nonapeptide, DYKDDDDKA) into the Nar I site of each Phase I mutant.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 1.
Sites of insertional mutation in
peripherin/rds. The primary sequence (346 amino acids) and current
folding topology model of bovine peripherin/rds are illustrated.
Fourteen individual Phase I mutants (numbered) were
constructed by the insertion of Nar I restriction sites at the
breakpoints indicated; Phase I mutations add a Gly-Ala dipeptide to the
WT sequence. Fourteen additional Phase II mutants were constructed by
directional ligation of an epitope cassette coding for a nonapeptide
FLAG epitope (DYKDDDDKA) into each Nar I site.
|
|
Heterologous Expression of Insertion Mutants in COS-1
Cells--
Each of the 28 mutant expression plasmids was
transfected individually into COS-1 cells in culture. Protein
expression was assessed by Western blot analysis using
anti-peripherin/rds MAb C6. This reagent is useful as a measure
of full-length protein expression because it recognizes a 15-amino acid
epitope at the C terminus of peripherin/rds. Although none of the
insertional mutations interrupt or lie immediately adjacent to the MAb
C6 epitope, it was not known a priori whether the antibody
would react with all mutants.
In fact, expression of each of the 14 Phase I mutants is detected by
MAb C6 in COS-1 cells. Similar to WT peripherin/rds, the mutants
typically migrate as closely spaced doublets under denaturing and
reducing conditions (Fig. 2A).
Moreover, peripherin/rds reactivity is also observed in extracts from
COS-1 cells transfected with each of the 14 Phase II mutants (Fig.
2B). The Phase II mutants migrate somewhat more slowly than
the WT protein and show a greater variation in electrophoretic
mobility. The added mass and charge of the FLAG epitope insertion,
heterogeneous post-translational modification, and/or residual
secondary structure may be responsible for the observed differences.
Identical results were obtained when Phase II mutant expression was
assayed by probing Western blots with the anti-FLAG MAb M2 (not shown).
Although we expected that the relatively large insertions introduced
into the Phase II mutants might cause degradation and absent or reduced
protein expression, reproducible differences in expression levels
between the Phase I and Phase II mutants were not observed. These
results demonstrate that neither minor (uncharged dipeptide) nor more major (charged hendecapeptide) insertions at any of 14 sites
distributed throughout the primary sequence prevent peripherin/rds
protein expression in COS-1 cells.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 2.
Assay of insertion mutant protein expression
by Western blot analysis. Detergent extracts of transfected COS-1
cells were reduced with -mercaptoethanol, run on a 10% SDS
polyacrylamide gel and then electroblotted onto Immobilon-P membrane
and probed with anti-peripherin/rds MAb C6. All 14 Phase I
(A) and 14 Phase II (B) insertion mutants express
peripherin/rds. Phase II mutants display reduced mobility relative to
WT due to the addition of a FLAG epitope; slight variations in apparent
molecular mass (MW) may be a function of
heterogeneous post-translational modification and/or residual secondary
structure.
|
|
WT peripherin/rds is extracted from vertebrate retina and COS-1 cells
both as monomeric and disulfide-bonded dimeric forms, as assayed by
nonreducing Western blot analysis. Abnormal disulfide bonding has been
associated with several instances of human retinal disease. We
therefore examined the mobility of each insertional mutant by Western
analysis in the absence of added reducing agent. Eleven of the 14 Phase
I mutants appear roughly similar to WT; they migrate primarily as both
monomeric and dimeric forms (Fig. 3A). In contrast, three Phase
I mutants (IM5, IM7, and IM11) show a banding pattern dissimilar from
WT (Fig. 3A, lanes 5, 7, and 11). These mutants exhibit a strong tendency to form large
aggregates that remain trapped in the stacking gel. Essentially
identical results were obtained for the Phase II series of mutations
(Fig. 3B). The combined data indicate that neither Phase I
nor Phase II mutations at any of 11 insertion sites prevents normal
disulfide bonding but that a mutation at any one of three sites (IM5,
IM7, or IM11) disrupts normal disulfide bonding and destabilizes
protein structure.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 3.
Assay of insertion mutant disulfide bonding
by nonreducing Western blot analysis. Detergent extracts of
transfected COS-1 cells were treated with N-ethylmaleimide
to block free thiols, subjected to nonreducing 10% SDS-PAGE, and then
electroblotted onto Immobilon-P membrane and probed with
anti-peripherin/rds MAb C6. All 14 Phase I (A) and 14 Phase
II (B) insertion mutants are observed as several species.
Three mutants show a pronounced tendency relative to WT to form higher
order aggregates: IM5, IM7, and IM11. Similar results are observed for
the Phase I and Phase II mutations.
|
|
Assay of Insertion Mutant Subunit Assembly by Velocity
Sedimentation--
WT peripherin/rds is assembled as a tetrameric
protein in both retinal photoreceptors and transfected COS-1 cells.
Tetramerization appears to be essential for function as impaired
subunit assembly has been linked to dysmorphic OSs in mice and several
forms of retinal degeneration in humans (24, 27). We have previously developed a reliable method for the assay of tetramer formation in
COS-1 by characterizing protein sedimentation velocity (29) and apply
it here to determine whether any of the insertional mutations affect
this process.
Phase I and Phase II mutants were centrifuged through sucrose density
gradients, and fractionated gradients were analyzed by Western blotting
using MAb C6. This approach generated sedimentation profiles that fall
into four main classes; raw data for particular Phase II mutants
typical of each class are presented (Fig.
4, B-E). A
representative sedimentation profile for WT peripherin/rds is given for
comparison (Fig. 4A). Sedimentation coefficients (S20, w values) calculated for each
hydrodynamically distinct species observed are presented in Table
II.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 4.
Assay of Phase II mutant subunit assembly by
velocity sedimentation. Detergent extracts from transiently
transfected COS-1 cell cultures were sedimented under reducing
conditions in 5-20% (w/w) sucrose gradients. Fractionated gradients
and particulate fractions (P) were assayed for
peripherin/rds by Western blot analysis with MAb C6. Chemiluminescent
blots and corresponding plots generated by image analysis are shown
(A-E); four classes of sedimentation profile are
evident. WT peripherin/rds (A) sediments as a single major
peak characteristic of a tetrameric stoichiometry (24). Most
insertional mutants, including IM9 (C), gave similar
results, indicating that their subunit assembly is normal. Two mutants,
including IM10 (D), displayed sedimentation profiles more
characteristic of dimeric peripherin/rds (37). Insertions at two sites,
including IM7 (B), caused gross aggregation as protein was
only recovered from the particulate fraction (P). Insertion
at one site, IM11 (E), was characterized by variable
behavior. Both dimeric and aggregated species are evident; this site
appears to destabilize protein structure in a significant yet
incomplete fashion. Sedimentation coefficient estimates for all 28 Phase I and Phase II mutants were calculated as described previously
(24) and are reported in Table II.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Sedimentation coefficients (S20, w) of peripherin/rds mutants
Sedimentation coefficients (S20, w) for peripherin/rds
variants expressed in COS-1 cells were determined as described under
"Experimental Procedures." The number of independent
transfection/sedimentation trials performed to obtain each value is
given by n; standard deviations are given where appropriate.
Mutants that were recovered from the particulate fraction are indicated
(P).
|
|
Neither Phase I nor Phase II insertional mutations affected velocity
sedimentation profiles at most (9 of 14) sites, including IM1, IM2,
IM3, IM4, IM6, IM9, IM12, IM13, and IM14. All were essentially indistinguishable from WT (Fig. 4, A and B and
Table II). These sites are distributed throughout the polypeptide
primary sequence (Fig. 1), and their lack of effect demonstrates that
subregions within every predicted hydrophilic domain can tolerate both
small (uncharged) and large (highly charged) insertional mutations
without global disruption of WT structure.
In contrast, either large or small insertions into any one of five
sites, all contained within the EC2 domain, resulted in largely non-WT
sedimentation behavior. Insertions into two sites, IM5 and IM7, caused
increased sedimentation velocities and recovery of the aggregated
mutants from the particulate fraction (Fig. 4B and Table
II). These effects illustrate sites at which insertional mutations
sufficiently reduce protein structural stability to generate global
misfolding. More interestingly, mutants at IM8 and IM10 sediment
with a velocity substantially less than that of WT (Fig. 4D
and Table II). Mutations at these sites result in sedimentation
coefficients that are more characteristic of peripherin/rds dimers than
tetramers, and they appear to disrupt normal subunit assembly without
impairing protein folding. Finally, IM11 mutants revealed more complex
and variable behavior than insertions in other sites (Fig.
4E). Phase I (IM11) insertions generated both grossly
misfolded and WT species, in an approximately equal ratio, whereas
Phase II (IM11) insertions produced variable amounts of aggregated
protein and hydrodynamic species of variable (non-WT) mobility (Fig.
4E and Table II). In sum, these results demonstrate that
insertional mutations at five of seven sites within EC2 cause
measurable changes in protein structure; these insertions produced
either global structural disruption (IM5 and IM7), altered subunit
assembly (IM8 and IM10), or both (IM11).
Subcellular Localization of Insertion Mutants by Immunofluorescence
Microscopy--
WT peripherin/rds expressed in COS-1 cells is retained
largely within intracellular membranes; a previous study (23) reported a distinctly perinuclear subcellular distribution and suggested that
the protein was localized within the Golgi apparatus. Our more recent
co-localization studies utilize a Golgi-specific marker and support
this interpretation.2 Because
quality control mechanisms are known to prevent misfolded membrane
proteins from exiting the endoplasmic reticulum and entering the Golgi
apparatus (32), we speculated that mutations that alter peripherin/rds
folding and subunit assembly might also affect its subcellular localization.
We used immunofluorescence microscopy to examine whether insertions in
EC2 that were disruptive for protein folding or assembly also affected
subcellular localization. It should be noted that fluorescence
localization patterns vary widely over populations of transfected
cells, and the images presented (Fig. 5) are representative of
the most commonly observed distribution for each variant. Because results were similar for Phase I and Phase II mutations, raw data are
presented for selected Phase II mutants only.
The subcellular distribution of WT peripherin/rds is shown for
comparison; the protein displays a stereotypical Golgi localization pattern, forming a small "cap" over the nuclei of expressing COS-1 cells (Fig. 5). Not surprisingly,
insertional mutants that do not affect protein folding or subunit
assembly (IM2 and IM9) generate fluorescence distributions similar to
WT. In addition, mutants that appear to preserve normal folding but
alter subunit assembly (IM8 and IM10) also show WT distributions. These
results indicate that tetramerization is not required for export from
the endoplasmic reticulum. In contrast, a pattern strikingly dissimilar
from WT is observed for those mutants that inhibit normal folding and cause protein aggregation (IM5, IM7, and IM11). Mutations at these sites produce large blobs of peripherin/rds that tend to encircle the
nuclei. The extent to which blobs were present was variable; in the
most extreme cases, the cytoplasm of the expressing cells was virtually
blob-filled. This type of labeling was rarely if ever observed for
other insertion mutants or WT peripherin/rds. These results demonstrate
that subcellular localization patterns of peripherin/rds are altered by
mutations that disrupt protein folding but not subunit assembly.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 5.
Subcellular localization of Phase II
insertion mutants by indirect immunofluorescence microscopy. COS-1
cells transiently transfected with the indicated mutant expression
vectors were fixed with paraformaldehyde, permeabilized with Triton
X-100, and labeled with anti-peripherin/rds MAb C6. WT peripherin/rds
(A) has previously been localized to internal membranes, a
perinuclear localization pattern typical of distribution within Golgi
membranes is apparent. Insertional mutations that do not result in
grossly misfolded protein, including IM2 (B), IM8
(E), IM9 (F), and IM10 (G), display
similar perinuclear distributions. Insertions that do result in grossly
misfolded protein, including IM5 (C), IM7 (D),
and IM11 (H), produce larger and more numerous fluorescent
blobs that are distributed less focally and are characteristic of
localization within the endoplasmic reticulum.
|
|
 |
DISCUSSION |
The EC2 region of peripherin/rds has been the subject of
considerable previous attention; it was there that the rds
defect was discovered and also there that the first human
disease-related defects were described (5). More recent studies of
recombinant peripherin/rds in COS-1 support the notion that this region
is highly significant (24, 25, 27, 29, 33, 34). The current investigation uses two series of insertional mutations distributed throughout the peripherin/rds polypeptide sequence to assess the relative importance of the EC2 region for protein structure. We find
that EC2 is critical for proper protein folding and that specific
determinants within this region guide tetrameric subunit assembly.
Insertional mutations at 9 of 14 sites distributed throughout the
peripherin/rds polypeptide sequence (IM1, IM2, IM3, IM4, IM6, IM9,
IM12, IM13, and IM14) had no discernible effect on protein folding or
subunit assembly in COS-1 cells (Fig. 6,
white ovals). These mutations did not prevent protein
expression, impair disulfide-mediated dimerization or tetrameric
subunit assembly, or prevent Golgi processing, and they include sites
both within and outside of the EC2 domain. These results suggest that
regions other than EC2 make relatively minor contributions to folding
and subunit assembly. The observed lack of effects may also reflect the
limited resolution of our experimental design. Spacing between sites of insertional mutation in hydrophilic domains ranged from 10 to 25 amino
acids, and the intervening sequences may contain additional areas of
consequence. Since our goal was to identify regions that make specific
local contributions, insertion sites were designed where possible to
lie outside the boundaries of strongly predicted secondary structures.
For example, we avoided disrupting a predicted amphipathic helix in the
C terminus that displays fusogenic activity in vitro (35).
Our data do not exclude the possibility that this as well as other
region(s) may contribute to the folding and subunit assembly of
peripherin/rds.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
Molecular consequences of insertional
mutations on peripherin/rds structure. Combined findings from
investigations of disulfide bonding, subunit assembly, and subcellular
localization are integrated to summarize current conclusions. The
majority of peripherin/rds polypeptide sequence can tolerate either
small uncharged (dipeptide) or larger, negatively charged
(hendecapeptide) insertions without measurable effects on protein
folding or tetrameric subunit assembly (white ovals).
Mutations that do affect protein structure all reside within EC2, the
second extracellular/intradiskal domain. Insertions caused either
grossly misfolded protein (black ovals) or dimeric
(versus tetrameric) subunit assembly (gray
ovals). One site, IM11, produced each effect at variable
ratios.
|
|
Insertions at IM5 and IM7 consistently caused abnormal disulfide
bonding, retention within the endoplasmic reticulum, and irreversible
protein aggregation. We conclude that these proteins are grossly
misfolded (Fig. 6, black ovals). A previous study (24)
pointed out the importance of EC2 for recombinant protein structure;
rapidly sedimenting species and protein trapped in stacking gels
suggested that substitution of any one of six conserved cysteines (by
serine) caused protein instability and aggregation. We expect that
grossly misfolded peripherin/rds would generally be retained and
eventually degraded within the endoplasmic reticulum and produce
retinal disease by haploinsufficiency. Alternatively, if misfolded
protein preserved some ability to form covalent and/or noncovalent
interactions with WT peripherin/rds, a dominant negative effect would
be predicted. Although not directly examined here, we propose that a
graded capacity of misfolded and WT protein to interact represents a
potential mechanism for producing phenotypic heterogeneity in
peripherin/rds-associated retinal disease.
Mutations at two sites, IM8 and IM10 (Fig. 6, gray ovals),
inhibit normal tetrameric subunit assembly and produce proteins with
significantly decreased sedimentation coefficients. Since these
molecules are characterized by normal solubility and disulfide bonding,
we conclude that they are essentially properly folded but contain
disruptions in regions required for tetrameric assembly. They, similar
to an L185P mutation associated with defective subunit assembly and
digenic retinitis pigmentosa (27, 36), display sedimentation
coefficients most characteristic of a dimeric stoichiometry (37). We
were somewhat surprised to find these mutants released to the Golgi
because quality control mechanisms typically retain incompletely
assembled oligomeric membrane proteins within the endoplasmic reticulum
(32). These observations raise the possibility that WT peripherin/rds
is also exported from the endoplasmic reticulum in a dimeric form and
that tetramerization normally occurs in the Golgi. Polytopic membrane
protein oligomerization in the Golgi has been documented previously
(38). The recent finding that the EC2 region of CD81, a tetraspanin
superfamily member related to peripherin/rds, crystallizes in a dimeric
form (39) indicates that self-assembly is a general property of the
tetraspanins, and this finding strengthens the likelihood that
peripherin/rds subunit assembly represents a dimerization of dimers
(37). At least two fates can be envisioned for dimerized
peripherin/rds. Previous studies (27, 36) have shown that L185P
dimers can be recruited (rescued) into normally sedimenting tetramers
by rom-1 or WT peripherin/rds; in this example, little or no disease phenotype is displayed. Alternatively, some pathogenic mutations may
prevent a rescue of the dimerized protein; it might be recycled into
the endoplasmic reticulum for degradation or perhaps be exported to the OS. The possibility that incompletely assembled protein (dimers)
could participate in OS renewal in a deficient fashion (i.e.
a partial function mutation) offers a second putative mechanism for the
generation of variability in peripherin/rdsrelated disease.
Mutations at one site within EC2, IM11, produced both protein
misfolding-retention within the endoplasmic reticulum and altered subunit assembly in variable ratios (Fig. 6, black/white/gray oval). The proximity of this site to an essential cysteine and the
interexperimental variability displayed suggest that a frequent but
incomplete failure to form proper disulfide bonds causes substantial protein misfolding; the variable population of protein molecules that
do fold appear to be heterogeneous in size. We speculate that
comparable fractional misfolding in photoreceptors might constitute a
third mechanism that contributes to phenotypic heterogeneity in
individuals with inherited defects in peripherin/rds.
Our current observations (that disruption of normal disulfide formation
and folding are caused by the mutation of EC2 but not other regions)
are consistent with previous reports and support the notion that EC2
plays a predominant role in structuring this molecule. These results
are generally reminiscent of findings for rhodopsin. Insertions into
cytoplasmic domains were generally nondisruptive, but
extracellular/intradiskal regions, including a cysteine pair involved
in a disulfide bond, were found to be crucial for structure and
function (28, 40, 41). EC2 has previously been proposed to be
structurally significant (34). The finding that peripherin/rds and the
homologous polypeptide, rom-1, assembled both with themselves and with
each other led to the hypothesis that subunit interactions may be
mediated by conserved structural motifs within their EC2 regions (23).
The structural (versus functional) importance of this region
was also demonstrated by the effects of a chimeric protein in
transgenic mice; that study (34) found that the peripherin/rds EC2
region (in a rom-1 context) was necessary, yet not sufficient, for
rescue of the rds phenotype. We interpret those results to
reflect both the presence of structural determinants within EC2 regions
of peripherin/rds and rom-1 and the existence of a region that is required for protein function, which is distinct from EC2 and is found
only in peripherin/rds.
Every region of peripherin/rds has now been associated with human
retinal disease; more than 40 pathogenic mutations have been reported
to date (5). Thus, it is not unexpected that most of the 14 insertional
mutation sites described here lie proximal (or adjacent) to one or
another disease-associated defect. Consistent rules for predicting
disease phenotype based on whether a defect causes gross protein
misfolding or merely impairs subunit assembly are not apparent from
inspection of the current data. Interestingly, pathogenic defects also
lie near to several sites (i.e. IM1, IM4, IM6, IM9, IM12,
and IM13) that do not affect structure as measured here. Although this
may merely reflect insensitivity of our methods, it may also indicate
sites of primarily functional (versus structural) significance.
The current report demonstrates that defects in peripherin/rds can
cause discrete and local, rather than global, disruptions of protein
structure. Moreover, our findings reveal that a variety of molecular
consequences are available to non-WT peripherin/rds. These results,
along with an emerging picture of specialized functional domains in
peripherin/rds, lead us to speculate that inherited defects can
preferentially affect one or another aspect of the overall
photoreceptor OS renewal process to generate heterogeneous retinal
pathophysiologies. This report initiates a systematic process for
defining domain structure-function relationships to test whether
positive correlations can be made between particular classes of
disruption and characteristic disease phenotypes.
 |
ACKNOWLEDGEMENTS |
The MAb C6 hybridoma line was generously
provided by Dr. Jack Saari and Dr. Krzysztof Palczewski; synthetic
peptides were a kind gift of Dr. Kathleen Boesze-Battaglia. We thank
Dr. Visvanathan Ramamurthy, Dr. Joseph Corless, Dr. Shu-Chu
Chen, Dr. Jing Huang, Daniel Possin, Timothy Bruggeman, and
the spirit of Linda Munar for technical assistance and discussion.
 |
FOOTNOTES |
*
This work was supported by generous grants (Grants
NIH R01 EY13246 to A. F. X. G . and NIH R01 EY06641 to J. B. H.)
from the NEI National Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Eye Research
Institute, Oakland University, Rochester, MI 48309. Tel.: 248-370-2393; Fax: 248-370-2006; E-mail: goldberg@oakland.edu.
Published, JBC Papers in Press, September 11, 2001, DOI 10.1074/jbc.M107511200
2
N. Khattree and A. Goldberg, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
OS, outer segment;
EC2, extracellular/intradiskal loop 2;
MAb, monoclonal antibody;
WT, wild-type;
rds, retinal degeneration slow;
IM, insertional mutant.
 |
REFERENCES |
| 1.
|
Young, R. W.
(1976)
Invest. Ophthalmol. Vis. Sci.
15,
700-725[Free Full Text]
|
| 2.
|
Molday, R. S.,
Hicks, D.,
and Molday, L.
(1987)
Invest. Ophthalmol. Vis. Sci.
28,
50-61[Abstract/Free Full Text]
|
| 3.
|
Travis, G. H.,
Brennan, M. B.,
Danielson, P. E.,
Kozak, C. A.,
and Sutcliffe, J. G.
(1989)
Nature
338,
70-73[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Sanyal, S.,
and Jansen, H. G.
(1981)
Neurosci. Lett.
21,
23-26[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Kohl, S.,
Giddings, I.,
Besch, D.,
Apfelstedt-Sylla, E.,
Zrenner, E.,
and Wissinger, B.
(1998)
Acta Anat. (Basel)
162,
75-84[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Arikawa, K.,
Molday, L. L.,
Molday, R. S.,
and Williams, D. S.
(1992)
J. Cell Biol.
116,
659-667[Abstract/Free Full Text]
|
| 7.
|
Travis, G. H.,
Groshan, K. R.,
Lloyd, M.,
and Bok, D.
(1992)
Neuron
9,
113-119[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Travis, G. H.,
Sutcliffe, J. G.,
and Bok, D.
(1991)
Neuron
6,
61-70[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Molday, R. S.
(1998)
Invest. Ophthalmol. Vis. Sci.
39,
2491-2513[Medline]
[Order article via Infotrieve]
|
| 10.
|
Goldberg, A. F.,
and Molday, R. S.
(1996)
Biochemistry
35,
6144-6149[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Boesze-Battaglia, K.,
Lamba, O. P.,
Napoli, A. A., Jr.,
Sinha, S.,
and Guo, Y.
(1998)
Biochemistry
37,
9477-9487[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Ali, R. R.,
Sarra, G. M.,
Stephens, C.,
Alwis, M. D.,
Bainbridge, J. W.,
Munro, P. M.,
Fauser, S.,
Reichel, M. B.,
Kinnon, C.,
Hunt, D. M.,
Bhattacharya, S. S.,
and Thrasher, A. J.
(2000)
Nat. Genet.
25,
306-310[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Wrigley, J. D.,
Ahmed, T.,
Nevett, C. L.,
and Findlay, J. B.
(2000)
J. Biol. Chem.
275,
13191-13194[Abstract/Free Full Text]
|
| 14.
|
Travis, G. H.,
Christerson, L.,
Danielson, P. E.,
Klisak, I.,
Sparkes, R. S.,
Hahn, L. B.,
Dryja, T. P.,
and Sutcliffe, J. G.
(1991)
Genomics
10,
733-739[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Moghrabi, W. N.,
Kedzierski, W.,
and Travis, G. H.
(1995)
Exp. Eye Res.
61,
641-643[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Kedzierski, W.,
Moghrabi, W. N.,
Allen, A. C.,
Jablonski-Stiemke, M. M.,
Azarian, S. M.,
Bok, D.,
and Travis, G. H.
(1996)
J. Cell Sci.
109,
2551-2560[Abstract]
|
| 17.
|
Weng, J.,
Belecky-Adams, T.,
Adler, R.,
and Travis, G. H.
(1998)
Invest. Ophthalmol. Vis. Sci.
39,
440-443[Abstract/Free Full Text]
|
| 18.
|
Connell, G. J.,
and Molday, R. S.
(1990)
Biochemistry
29,
4691-4698[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Bascom, R. A.,
Manara, S.,
Collins, L.,
Molday, R. S.,
Kalnins, V. I.,
and McInnes, R. R.
(1992)
Neuron
8,
1171-1184[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Gorin, M. B.,
Snyder, S.,
To, A.,
Narfstrom, K.,
and Curtis, R.
(1993)
Mamm. Genome
4,
544-548[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Moritz, O. L.,
and Molday, R. S.
(1996)
Invest. Ophthalmol. Vis. Sci.
37,
352-362[Abstract/Free Full Text]
|
| 22.
|
Gould, D. J.,
Petersen-Jones, S. M.,
Lin, C. T.,
and Sargan, D. R.
(1997)
Anim. Genet.
28,
391-396[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Goldberg, A. F.,
Moritz, O. L.,
and Molday, R. S.
(1995)
Biochemistry
34,
14213-14219[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Goldberg, A. F.,
Loewen, C. J.,
and Molday, R. S.
(1998)
Biochemistry
37,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Loewen, C. J.,
and Molday, R. S.
(2000)
J. Biol. Chem.
275,
5370-5378[Abstract/Free Full Text]
|
| 26.
|
Clarke, G.,
Goldberg, A. F.,
Vidgen, D.,
Collins, L.,
Ploder, L.,
Schwarz, L.,
Molday, L. L.,
Rossant, J.,
Szel, A.,
Molday, R. S.,
Birch, D. G.,
and McInnes, R. R.
(2000)
Nat. Genet.
25,
67-73[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Goldberg, A. F.,
and Molday, R. S.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
13726-13730[Abstract/Free Full Text]
|
| 28.
|
Borjigin, J.,
and Nathans, J.
(1994)
J. Biol. Chem.
269,
14715-14722[Abstract/Free Full Text]
|
| 29.
|
Goldberg, A. F.,
and Molday, R. S.
(2000)
Methods Enzymol.
316,
671-687[Medline]
[Order article via Infotrieve]
|
| 30.
|
Chubet, R. G.,
and Brizzard, B. L.
(1996)
BioTechniques
20,
136-141[Medline]
[Order article via Infotrieve]
|
| 31.
|
Smith, D. B.,
and Johnson, K. S.
(1988)
Gene (Amst.)
67,
31-40[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Ellgaard, L.,
Molinari, M.,
and Helenius, A.
(1999)
Science
286,
1882-1888[Abstract/Free Full Text]
|
| 33.
|
Kedzierski, W.,
Lloyd, M.,
Birch, D. G.,
Bok, D.,
and Travis, G. H.
(1997)
Invest. Ophthalmol. Vis. Sci.
38,
498-509[Abstract/Free Full Text]
|
| 34.
|
Kedzierski, W.,
Weng, J.,
and Travis, G. H.
(1999)
J. Biol. Chem.
274,
29181-29187[Abstract/Free Full Text]
|
| 35.
|
Boesze-Battaglia, K.,
Stefano, F. P.,
Fenner, M.,
and Napoli, A. A., Jr.
(2000)
Biochim. Biophys. Acta
1463,
343-354[Medline]
[Order article via Infotrieve]
|
| 36.
|
Kajiwara, K.,
Berson, E. L.,
and Dryja, T. P.
(1994)
Science
264,
1604-1608[Abstract/Free Full Text]
|
| 37.
|
Loewen, C. J.,
Moritz, O. L.,
and Molday, R. S.
(2001)
J. Biol. Chem.
276,
22388-22396[Abstract/Free Full Text]
|
| 38.
|
Musil, L. S.,
and Goodenough, D. A.
(1993)
Cell
74,
1065-1077[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Kitadokoro, K.,
Bordo, D.,
Galli, G.,
Petracca, R.,
Falugi, F.,
Abrignani, S.,
Grandi, G.,
and Bolognesi, M.
(2001)
EMBO J.
20,
12-18[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Karnik, S. S.,
and Khorana, H. G.
(1990)
J. Biol. Chem.
265,
17520-17524[Abstract/Free Full Text]
|
| 41.
|
Doi, T.,
Molday, R. S.,
and Khorana, H. G.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
4991-4995[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. P. Lim, S. P. Yip, S. C. Cheung, K. W. Leung, S. T. S. Lam, and C. H. To
Novel PRPF31 and PRPH2 Mutations and Co-occurrence of PRPF31 and RHO Mutations in Chinese Patients With Retinitis Pigmentosa
Arch Ophthalmol,
June 1, 2009;
127(6):
784 - 790.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. F. X. Goldberg, L. M. Ritter, N. Khattree, N. S. Peachey, R. N. Fariss, L. Dang, M. Yu, and A. R. Bottrell
An Intramembrane Glutamic Acid Governs Peripherin/rds Function for Photoreceptor Disk Morphogenesis
Invest. Ophthalmol. Vis. Sci.,
July 1, 2007;
48(7):
2975 - 2986.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Damek-Poprawa, J. Krouse, C. Gretzula, and K. Boesze-Battaglia
A Novel Tetraspanin Fusion Protein, Peripherin-2, Requires a Region Upstream of the Fusion Domain for Activity
J. Biol. Chem.,
March 11, 2005;
280(10):
9217 - 9224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Ritter, K. Boesze-Battaglia, B. M. Tam, O. L. Moritz, N. Khattree, S.-C. Chen, and A. F. X. Goldberg
Uncoupling of Photoreceptor Peripherin/rds Fusogenic Activity from Biosynthesis, Subunit Assembly, and Targeting: A POTENTIAL MECHANISM FOR PATHOGENIC EFFECTS
J. Biol. Chem.,
September 17, 2004;
279(38):
39958 - 39967.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-Q. Ding, M. Nour, L. M. Ritter, A. F.X. Goldberg, S. J. Fliesler, and M. I. Naash
The R172W mutation in peripherin/rds causes a cone-rod dystrophy in transgenic mice
Hum. Mol. Genet.,
September 15, 2004;
13(18):
2075 - 2087.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|